Erratum

Erratum to “Fibromyalgia Syndrome: Etiology, Pathogenesis, Diagnosis, and Treatment”

Table 3

Comparison between American Pain Society (APS) and Association of the Scientific Medical Societies in Germany (AWMF) with European League Against Rheumatism (EULAR).

Nonpharmacologic treatmentMedications

American Pain Society (APS) and Association of the Scientific Medical Societies in Germany (AWMF) Strong evidence:Strong evidence:
Patient education
CBT
Aerobic exercise
Multidisciplinary therapy
Amitriptyline (25/50 mg)
 NNT 3,54 (95% CI 2.74, 5.01)
Cyclobenzaprine (10/30 mg)
Moderate evidence:Moderate evidence:
Strength training
Acupuncture
Hypnotherapy
Biofeedback
Balneotherapy
SNRIs:
 Milnacipran (100 mg)
  NNT 19 (95% CI 7.4, 20.5)
  NNH 7.6 (95% CI 6.2, 9.9)
 Duloxetine (60/120 mg)
  NNT 7.2 (95% CI 5.2, 11.4)
  NNH 14.9 (95% CI 9.1, 41.4)
 SSRI:
  Fluoxetine (20/80 mg)
  Tramadol (200/300 mg)
Anticonvulsant:
 Pregabalin (300/450 mg)
  NNT 8.6 (95% CI 6.4, 12.9)
  NNH 7.6 (95%CI 6.3, 9.4)

European League Against Rheumatism (EULAR)Balneotherapy (grade B)
Individually tailored exercise including aerobic and strength training (grade C)
Cognitive-behavioral therapy (grade B)
Others: relaxation, rehabilitation, physiotherapy, and/or psychological support (grade C)
Tramadol (grade A)
Analgesics (paracetamol/acetaminophen, weak opioids) (grade D)
Antidepressants (amitriptyline, fluoxetine, duloxetine, milnacipran, moclobemide, pirlindole) (grade A)
Tropisetron, pramipexole, pregabalin (grade A)